Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Almirall obtains approval from EC for atopic dermatitis therapy
EBGLYSS is intended for patients aged 12 years and above who are candidates for systemic therapy. The company plans to begin selling the product in Germany initially and
EBGLYSS is intended for patients aged 12 years and above who are candidates for systemic therapy. The company plans to begin selling the product in Germany initially and
Homology Medicines will issue shares of its common stock to Q32 Bio stockholders as part of the merger deal, in return for cancelling Q32 Bio’s capital stock. Pre-merger
The company has also enrolled the first US patient in a Phase Ib/IIa clinical study to assess XTMAB-16 for the treatment of patients with pulmonary sarcoidosis. Pulmonary sarcoidosis
The first and only FDA-approved ready-to-use oral liquid metronidazole in the country, LIKMEZ is intended for patients who may struggle with dysphagia, difficulty swallowing, or high taste sensitivities.
The company filed the application to manufacture and sell the second-generation oral calcineurin inhibitor, voclosporin, in Japan. In January 2021, voclosporin along with a background immunosuppressive therapy regimen
A clinical stage pipeline asset for the company, LP-310 is intended to be indicated for inflammatory diseases of the oral cavity, including oral lichen planus and oral GvHD.
Ixchiq is approved to be used for individuals aged 18 years and above at increased risk of exposure to the virus. Administered as a single dose by injection
The investigational CD19 CAR-T cell therapy received approval to treat patients with relapsed and refractory B-cell acute lymphoblastic leukemia (r/r B-ALL) in China. Inaticabtagene Autoleucel uses CMC manufacturing
This latest funding round has increased the company’s total capital raised to $97m. Co-led by Longitude Capital and Enavate Sciences, this round saw participation from existing investors Samsara
Halozyme’s ENHANZE is a recombinant human hyaluronidase PH20 enzyme (rHuPH20) for quick subcutaneous drug delivery. Acumen plans to evaluate the potential application of this technology in the development